Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Voyager Therapeutics, Inc. Common Stock

VYGR

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

Last trade $1.54
Day change -$0.09 (-5.52%)
Day range $1.52 – $1.67
Volume 715,979
Market cap $101M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$101.43M
Price / earnings
—
Price / book
0.75×
Price / sales
4.04×
EV / sales
2.11×
EV / EBITDA
-0.49×

Profitability

Earnings per share
-$1.68
Return on assets
-59.21%
Return on equity
-77.58%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
6.81×
Quick ratio
6.81×
Cash ratio
2.88×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$109.83M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VYGR, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$4.01M$3.17M$2.59M$15.34M$13.37M$5.2M$6.47M$6.28M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$4.01M$3.17M$2.59M$15.34M$13.37M$5.2M$6.47M$6.28M
Selling, general and administrative$6.07M$7.52M$8.26M$9.32M$8.09M$10.5M$9.64M$8.99M
Research and development$24.37M$22.04M$24.6M$35.95M$35.87M$31.33M$31.53M$35.58M
Total operating expenses$30.44M$29.56M$32.86M$45.27M$43.96M$41.83M$41.17M$44.58M
Operating income-$26.42M-$26.39M-$30.27M-$29.93M-$30.59M-$36.63M-$34.69M-$38.3M
Interest expense$1.34M$1.53M$0$0$2.39M$2.83M$0$0
Income before taxes-$24.68M-$24.45M-$27.92M-$27.42M-$27.81M-$33.37M-$30.98M-$33.9M
Income taxes$18K$20K$14K$9K$83K$15K$37K$584K
Net income-$24.69M-$24.47M-$27.94M-$27.43M-$27.89M-$33.38M-$31.02M-$34.49M
Net income attributable to common shareholders-$24.69M-$24.47M-$28.23M-$27.43M-$27.89M-$33.38M-$30.81M-$34.49M
EBITDA-$25.59M-$25.48M-$29.34M-$28.88M-$29.66M-$35.56M-$33.68M-$37.29M
Basic earnings per share-$0.40-$0.40-$0.47-$0.47-$0.47-$0.57-$0.53-$0.59
Diluted earnings per share-$0.40-$0.40-$0.47-$0.47-$0.47-$0.57-$0.53-$0.59

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight

Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

GlobeNewswire Inc.

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

Voyager Therapeutics expanded its Alzheimer's disease franchise by introducing a new gene therapy program targeting APOE, complementing existing tau and amyloid assets. The program aims to reduce APOE4 variant expression while delivering the protective APOE2 variant using an innovative IV-delivered TRACER capsid.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.